NSC185058: an ATG4B antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 750538 |
| CHEMBL ID | 112597 |
| SCHEMBL ID | 2894809 |
| MeSH ID | M000609777 |
| Synonym |
|---|
| EU-0046459 |
| NCGC00078440-02 |
| MLS000756413-02 |
| 2-pyridinecarbothioamide, n-2-pyridinyl- |
| nsc185058 |
| 39122-38-8 |
| nsc-185058 |
| mls000756413 , |
| OPREA1_465351 |
| MLS000104342 , |
| smr000054277 |
| n-(pyridin-2-yl)pyridine-2-carbothioamide |
| STK326403 |
| AKOS000361102 |
| CHEMBL112597 |
| n-pyridin-2-ylpyridine-2-carbothioamide |
| HMS2307I19 |
| SCHEMBL2894809 |
| n-(2-pyridinyl)-2-pyridinecarbothioamide |
| bdbm34545 |
| n-(2-pyridyl)thiopicolinamide |
| cid_750538 |
| nsc 185058 |
| DTXSID80353743 |
| BS-16731 |
| BCP30689 |
| nsc-185058; nsc 185058;2-pyridinecarbothioamide, n-2-pyridinyl- |
| HY-125169 |
| CS-0089745 |
| mfcd00448857 |
| D70755 |
| EN300-214523 |
| Z1509144734 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 14.3484 | 0.0447 | 17.8581 | 100.0000 | AID485294; AID485341 |
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 14.0586 | 0.1409 | 11.1940 | 39.8107 | AID2451; AID2787 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 6.3096 | 0.0251 | 20.2376 | 39.8107 | AID886 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 6.3096 | 0.0251 | 20.2376 | 39.8107 | AID886 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 5.0119 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 17.4882 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 10.7656 | 0.0072 | 15.7588 | 89.3584 | AID411; AID588342 |
| Nrf2 | Homo sapiens (human) | Potency | 8.9125 | 0.0920 | 8.2222 | 23.1093 | AID624171 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 0.8913 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| BRCA1 | Homo sapiens (human) | Potency | 7.0795 | 0.8913 | 7.7225 | 25.1189 | AID624202 |
| WRN | Homo sapiens (human) | Potency | 56.2341 | 0.1683 | 31.2583 | 100.0000 | AID651768 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 21.2632 | 0.1413 | 37.9142 | 100.0000 | AID1490; AID2701; AID493214 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 9.8402 | 0.0041 | 10.8903 | 31.5287 | AID504466; AID504467 |
| GLS protein | Homo sapiens (human) | Potency | 35.4813 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
| TDP1 protein | Homo sapiens (human) | Potency | 0.9200 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 22.9833 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| Smad3 | Homo sapiens (human) | Potency | 15.0944 | 0.0052 | 7.8098 | 29.0929 | AID588855; AID720536 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 3.5481 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| hypothetical protein, conserved | Trypanosoma brucei | Potency | 35.4813 | 0.2239 | 11.2451 | 35.4813 | AID624173 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 12.5893 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
| 67.9K protein | Vaccinia virus | Potency | 25.2855 | 0.0001 | 8.4406 | 100.0000 | AID720579; AID720580 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 8.9716 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| P53 | Homo sapiens (human) | Potency | 30.1076 | 0.0731 | 9.6858 | 31.6228 | AID504706 |
| pyruvate kinase | Leishmania mexicana mexicana | Potency | 13.4270 | 0.3981 | 13.7447 | 31.6228 | AID1721; AID1722 |
| IDH1 | Homo sapiens (human) | Potency | 6.5131 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 0.6110 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| beta-2 adrenergic receptor | Homo sapiens (human) | Potency | 24.9896 | 0.0058 | 6.0263 | 32.6427 | AID492947 |
| lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 8.1167 | 0.0366 | 19.6376 | 50.1187 | AID2100 |
| NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 2.2016 | 0.0126 | 2.4518 | 25.0177 | AID485313 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 17.9008 | 0.3162 | 12.4435 | 31.6228 | AID902; AID924 |
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 8.9125 | 0.0018 | 15.6638 | 39.8107 | AID894 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 12.5893 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 2.5929 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
| glyceraldehyde-3-phosphate dehydrogenase isoform 1 | Homo sapiens (human) | Potency | 63.0957 | 1.1220 | 11.1877 | 39.8107 | AID2795 |
| pyruvate kinase PKM isoform a | Homo sapiens (human) | Potency | 15.8489 | 0.0401 | 7.4590 | 31.6228 | AID1631; AID1634 |
| ras-related protein Rab-9A | Homo sapiens (human) | Potency | 2.8371 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 26.6795 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 4.2381 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
| geminin | Homo sapiens (human) | Potency | 12.1294 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 19.9526 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 21.4509 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
| DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | Potency | 31.6228 | 0.0580 | 10.6949 | 26.6086 | AID602310 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 1.5830 | 0.0158 | 12.3113 | 615.5000 | AID1461; AID1489; AID2567 |
| Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 14.1254 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 15.8489 | 0.3162 | 11.4157 | 31.6228 | AID924 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 15.8489 | 0.3162 | 11.4157 | 31.6228 | AID924 |
| Endothelin receptor type B | Rattus norvegicus (Norway rat) | Potency | 13.4270 | 0.5623 | 15.1609 | 31.6228 | AID1721 |
| Endothelin-1 receptor | Rattus norvegicus (Norway rat) | Potency | 13.4270 | 0.5623 | 15.1609 | 31.6228 | AID1721 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 37.9330 | 0.0601 | 10.7453 | 37.9330 | AID485367 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Cysteine protease ATG4B | Homo sapiens (human) | IC50 (µMol) | 51.0000 | 0.6300 | 3.0655 | 8.9000 | AID1330872; AID1607788; AID1637688; AID1915513 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| nuclear factor NF-kappa-B p105 subunit isoform 1 | Homo sapiens (human) | EC50 (µMol) | 2.0280 | 0.0590 | 5.5596 | 27.2100 | AID1241 |
| transcription factor p65 isoform 1 | Homo sapiens (human) | EC50 (µMol) | 2.0280 | 0.0590 | 5.5596 | 27.2100 | AID1241 |
| Estrogen receptor beta | Mus musculus (house mouse) | EC50 (µMol) | 2.0280 | 0.0590 | 5.5596 | 27.2100 | AID1241 |
| Estrogen receptor | Mus musculus (house mouse) | EC50 (µMol) | 2.0280 | 0.0590 | 5.5596 | 27.2100 | AID1241 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1607788 | Inhibition of ATG4B (unknown origin) using GST-labelled LC3B as substrate after 24 hrs followed by substrate addition and measured after 3 mins by coomassie blue staining-based SDS-PAGE analysis | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178 | Identification of benzo[cd]indol-2(1H)-ones as novel Atg4B inhibitors via a structure-based virtual screening and a novel AlphaScreen assay. |
| AID1637688 | Inhibition of ATG4B (unknown origin) using LC3B-GST as substrate preincubated for 24 hrs followed by substrate addition measured after 3 mins by SDS-PAGE method | 2016 | ACS medicinal chemistry letters, Aug-11, Volume: 7, Issue:8 | Discovery of Fluoromethylketone-Based Peptidomimetics as Covalent ATG4B (Autophagin-1) Inhibitors. |
| AID1330873 | Inhibition of human recombinant GST-tagged Atg4B expressed in Escherichia coli at 500 uM using LC3B-GST as substrate after 6 mins by SDS-PAGE assay | 2016 | European journal of medicinal chemistry, Nov-10, Volume: 123 | Inhibitor screening and enzymatic activity determination for autophagy target Atg4B using a gel electrophoresis-based assay. |
| AID1330872 | Inhibition of Atg4B (unknown origin) using LC3B-GST as substrate preincubated for 24 hrs followed by substrate addition measured for 3 mins by SDS-PAGE assay | 2016 | European journal of medicinal chemistry, Nov-10, Volume: 123 | Inhibitor screening and enzymatic activity determination for autophagy target Atg4B using a gel electrophoresis-based assay. |
| AID177844 | Effective dose against ethanol-induced gastric lesions in male albino rat when given perorally was determined; 1.2-5.9 | 1990 | Journal of medicinal chemistry, Jan, Volume: 33, Issue:1 | N-phenyl-2-pyridinecarbothioamides as gastric mucosal protectants. |
| AID1915513 | Inhibition of ATG4B in human SAOS-2 cells using GFP-LC3B as substrate incubated for 6 hrs by by fluorescence microscopy | 2021 | European journal of medicinal chemistry, Jan-01, Volume: 209 | Targeting Atg4B for cancer therapy: Chemical mediators. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.64) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (8.33%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (91.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||